Blood Res.  2020 Sep;55(3):175-177. 10.5045/br.2020.2020045.

Successful response with romidepsin in relapsed peripheral T-cell lymphoma, not otherwise specified with leukemic progression

• Sato S
• Tamai Y

• KMID: 2507058
• DOI: http://doi.org/10.5045/br.2020.2020045

Abstract

No abstract available.

Figure

• 

  Fig. 1 Computed tomography (CT) findings at relapse showing splenomegaly (A). CT after 2 courses of romidepsin showing that the splenomegaly improved (B). Peripheral blood smear with May–Giemsa staining (C) and histopathological findings from bone marrow biopsy showing diffuse proliferation of medium-sized lymphoid cells (hematoxylin-eosin staining, ×20) (D), indicating a leukemic-phase peripheral T-cell lymphoma. Immunohistochemical staining expressed (E) CD3, (F) CD4 (weakly), and (G) CD8 lymphocytes.

Reference

1. Pileri SA, Orazi A, Falini B. Swerdlow SH, Campo E, Harris NL, editors. 2017. Myeloid sarcoma. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. France: IARC Press;Lyon: p. 167–8.

2. Rizvi MA, Evens AM, Tallman MS, Nelson BP, Rosen ST. 2006; T-cell non-Hodgkin lymphoma. Blood. 107:1255–64. DOI: 10.1182/blood-2005-03-1306. PMID: 16210342.

3. Foss FM, Zinzani PL, Vose JM, Gascoyne RD, Rosen ST, Tobinai K. 2011; Peripheral T-cell lymphoma. Blood. 117:6756–67. DOI: 10.1182/blood-2010-05-231548. PMID: 30596214.

4. Kawamoto K, Miyoshi H, Yanagida E, et al. 2017; Comparison of clinicopathological characteristics between T-cell prolymphocytic leukemia and peripheral T-cell lymphoma, not otherwise specified. Eur J Haematol. 98:459–66. DOI: 10.1111/ejh.12856. PMID: 28129454.

5. Coiffier B, Pro B, Prince HM, et al. 2012; Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 30:631–6. DOI: 10.1200/JCO.2011.37.4223. PMID: 22271479.

6. National Comprehensive Cancer Network. 2020. NCCN Guidelines. T-cell lymphomas. National Comprehensive Cancer Network;Plymouth Meeting, PA: at https://www.nccn.org/professionals/physician_gls/default.aspx. Accessed February 12, 2020.

7. Coiffier B, Pro B, Prince HM, et al. 2014; Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. J Hematol Oncol. 7:11. DOI: 10.1186/1756-8722-7-11. PMID: 24456586. PMCID: PMC4016573.

8. Piekarz RL, Frye R, Prince HM, et al. 2011; Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood. 177:5827–34. DOI: 10.1182/blood-2010-10-312603. PMID: 21355097. PMCID: PMC3112033.

9. Maruyama D, Tobinai K, Ogura M, et al. 2017; Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I/II and pharmacokinetics study. Int J Hematol. 106:655–65. DOI: 10.1007/s12185-017-2286-1. PMID: 28664499.

10. Brunvand MW, Carson J. 2018; Complete remission with romidepsin in a patient with T-cell acute lymphoblastic leukemia refractory to induction hyper-CVAD. Hematol Oncol. 36:340–3. DOI: 10.1002/hon.2421. PMID: 28560733. PMCID: PMC5836898.

11. Marchi E, Zullo KM, Amengual JE, et al. 2015; The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T-cell lymphoma. Br J Haematol. 171:215–26. DOI: 10.1111/bjh.13566. PMID: 26194163.

12. O'Connor OA, Zullo K, Marchi E, et al. 2015; Targeting epigenetic operations with HDAC inhibitor and hypomethylating drugs in combination exhibit synergy in preclinical and clinical experiences in drug resistant T-cell lymphoma (TCL): a translational focus on doublet development. Blood (ASH Annual Meeting Abstract). 126(Suppl):1282. DOI: 10.1182/blood.V126.23.1282.1282.